MGTX (MeiraGTx Corp) Net Sales Margin

Corporate emblem and logo of MeiraGTx (MGTX)

MeiraGTx Holdings plc (MGTX) is recognized as a leader in genetic modification, having earned authority among biomedical professionals. Its proprietary vector manufacturing plants strengthen the firm's position by minimizing risks during drug development. Revenues are based on therapies for neurodegenerative pathologies and retinal diseases. Financial sales margins demonstrate capital efficiency, while the 19.50 indicator reflects the status of current return on assets.

MeiraGTx Holdings plc (MGTX) - Company Sales Margin from 07/04/2022 to 11/20/2026

Metric breakdowns and analytics for MeiraGTx Corp (MGTX)

- market value and analyst target forecast:
Analysis of all company metrics:MeiraGTx, MGTX
Flagship merchandise of MeiraGTx PLC

MeiraGTx Holdings plc (MGTX) capacity to withstand operational downturns is limited by a lack of stable sales and a dependence on volatile payments from gene therapy partners. The current value of 19.50 for annual net margin reflects the portion of revenue remaining after all expenses, allowing investors to assess the real efficiency of the business; however, for a final conclusion, this data must be compared with the cost of capital.

Who MeiraGTx Holdings plc competes with

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX